Olema Shares Plummet After Roche’s Phase 3 Readout Falls Short
Shares of Olema Pharmaceuticals (NASDAQ:OLMA) tumbled 41% on Monday after Roche disclosed that its Phase 3 persevERA study failed to achieve a statistically significant improvement in progression-free survival for giredestrant plus palbociclib versus an aromatase inhibitor plus palbociclib. Roche said a numerical improvement was observed but it did…